23/03/2026
The rapid rise in the use of GLP-1 weight-loss medications in Australia is raising serious concerns.
While effective for weight loss and specific chronic disease management, up to 40% of the loss may come from lean muscle – increasing the risk of frailty and long-term harm.
ESSA CEO and Accredited Exercise Physiologist, Katie Lyndon said these medications must be used carefully. ESSA is calling on the Federal Government to mandate a referral to an Accredited Exercise Physiologist at the point of prescription.
"Skeletal muscle plays a critical role in strength, mobility and metabolic health. For older Australians or those living with chronic disease, rapid muscle loss without structured exercise support may accelerate frailty - increasing the risk of falls, loss of independence and serious decline in quality of life," Katie said.
Read our media release: https://bit.ly/41rUxHf
